Imagine a child born in a family with a rare disease, whose treatment would cost more than 17 crore for a single dose. The ...
Gene therapy is linked to better nonmotor outcomes in spinal muscular atrophy type 1 compared to first-line nusinersen, new ...
As their 8-month-old daughter prepares for gene therapy treatment, a Coon Rapids family is bracing for three months of ...
Dennis P. Scanlon, PhD; Emma Ciafaloni, MD; Maria Lopes, MD, MS; Kevin U. Stephens, Sr, JD, MD; and Mary Schroth, MD, FAAP, FCCP provide an overview of the disease burden in spinal muscular atrophy ...
Novartis is seeking to repurpose its investigational oral spinal muscular atrophy (SMA) drug branaplam to treat Huntington's disease, the Swiss drugmaker said on Wednesday, as it plans a clinical ...
In a huge setback for Swiss pharma major Roche, the Supreme Court on Friday dismissed its petition challenging a Delhi High ...
The Rare Disease Therapeutics Market is experiencing an unprecedented wave of innovation, driven by gene therapies, RNA-based ...
Biogen's Spinraza is not the first drug to face a CMC-related rejection recently, as SMA competitor drug, apitegromab, also got the FDA no-go ...
Scholar Rock (SRRK) stock gains as Bank of America launches its coverage with a Buy recommendation, citing a blockbuster potential for its lead drug. Read more here.
14don MSN
England rugby legend Moody diagnosed with MND: Understanding the disease, causes, and warning signs
Former England rugby captain Lewis Moody has been diagnosed with motor neurone disease (MND), a progressive condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback